COMMUNIQUÉS West-GlobeNewswire

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
18/06/2024
Celebrating the bold leaders who disrupt markets, revolutionize industries and transform lives SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Ernst & Young LLP (EY US) today announced that Scott Struthers, Ph.D., [...]
Neurona Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for NRTX-1001 in Focal Epilepsy
18/06/2024
- RMAT designation follows positive data update from the ongoing Phase 1/2 clinical trial of NRTX-1001 cell therapy, demonstrating a favorable safety profile to date and the potential to significantly reduce seizure [...]
Gyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
18/06/2024
SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ [...]
Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024
18/06/2024
MIAMI, FL, June 18, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, [...]
Pennant and Hartford HealthCare Partner to Transform Home Care Services
18/06/2024
EAGLE, Idaho, June 18, 2024 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of affiliated home health, hospice and senior living companies, announced today that it has [...]
Tevogen.AI Head Discusses Company’s Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT Conference
18/06/2024
WARREN, N.J., June 18, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically [...]
Capital Increase in Genmab as a Result of Employee Warrant Exercise
18/06/2024
Company Announcement COPENHAGEN, Denmark; June 18, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 6,986 shares as a consequence of the exercise of employee warrants. The increase is effected without [...]
Mika Health Collaborates with AstraZeneca and Daiichi Sankyo to Deliver AI-Enabled Mobile Support to Women Undergoing Breast Cancer Treatment
18/06/2024
Breast cancer patients in Switzerland will receive access to a personalized digital therapeutic designed to optimize their experience and health while on treatment AMSTERDAM, June 18, 2024 (GLOBE NEWSWIRE) -- Mika [...]
SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions
18/06/2024
MIAMI, June 18, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte [...]
"I Have Insurance, Why Can't I Afford My Oral Anticancer Medications?" International Myeloma Foundation Highlights the Urgent Need for Cancer Drug Parity Act at Congressional Briefing
18/06/2024
The Successful Briefing Addressed Insurance Coverage for Oral Anticancer Medications WASHINGTON, June 18, 2024 (GLOBE NEWSWIRE) -- The International Myeloma Foundation-led Coalition to Improve Access to Cancer Care ( [...]
EssilorLuxottica and Diesel announce a ten-year licensing agreement
18/06/2024
ESSILORLUXOTTICA AND DIESEL ANNOUNCE A TEN-YEAR LICENSING AGREEMENT Charenton-le-Pont, France and Milan, Italy (18 June 2024) – EssilorLuxottica and Diesel announced today that they have signed an exclusive license [...]
EssilorLuxottica et Diesel annoncent un accord de licence de 10 ans
18/06/2024
ESSILORLUXOTTICA ET DIESEL ANNONCENT UN ACCORD DE LICENCE DE 10 ANS Charenton-le-Pont, France et Milan, Italie (18 juin 2024) – EssilorLuxottica et Diesel annoncent aujourd’hui la signature d’un accord de licence [...]
Canadian Red Cross and The Resilience Institute launch new program to promote readiness
18/06/2024
Roots for Resilience to engage with small, rural and Indigenous communities OTTAWA, June 18, 2024 (GLOBE NEWSWIRE) -- The Canadian Red Cross and The Resilience Institute are pleased to announce a new partnership that [...]
La Croix-Rouge canadienne et le Resilience Institute s’unissent pour lancer un programme de préparation destiné aux communautés rurales, autochtones ou moins peuplées : Roots for Resilience
18/06/2024
OTTAWA, 18 juin 2024 (GLOBE NEWSWIRE) -- La Croix-Rouge canadienne et le Resilience Institute ont le plaisir d’annoncer un nouveau partenariat visant à renforcer la résilience climatique des communautés rurales, [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024
18/06/2024
Aggregated presentation by day and by market Purchases of own shares from June 10th to 14th 2024 Name of the Issuer Identity code of the Issuer Day of the transaction Identity code of the financial instrument Total [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 24 - 2024
18/06/2024
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 10 au 14 juin 2024 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction Code [...]
Actions to strengthen presence in North Africa : Congress & Surgeons trainings
18/06/2024
Press release Ecully, June 18, 2024 – 6 p.m. Presentation of the KAPHORN system to 200 surgeons at the SOTCOT Congress in Hammamet The Spineway Group, a specialist in innovative implants for the treatment of severe [...]
Actions de développement de la zone Moyen-Orient : congrès et formation chirurgiens
18/06/2024
Communiqué de presse Ecully, le 18 juin 2024 – 18h Présentation du système KAPHORN devant 200 chirurgiens au congrès de la SOTCOT à Hammamet Le groupe Spineway spécialiste des implants innovants pour le traitement des [...]
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer
18/06/2024
Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy AUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT [...]

Pages